Dermata Therapeutics Shares Drop Despite Positive Cosmetic Study Results for Tome
Dermata Therapeutics, Inc. (DRMA) announced positive topline results from an open-label cosmetic clinical trial evaluating its once-weekly skin treatment, Tome Foundational Treatment. The four-week study enrolled 31 participants to assess improvements in skin appearance across measures such as fine lines, hyperpigmentation, dark spots, smoothness, firmness, and radiance. Over 71% of participants showed overall skin improvement after a single application, and no treatment-related adverse events were reported.
The findings offer clinical backing for Dermata's direct-to-consumer skincare line, which features its proprietary Bioneedle technology derived from freshwater sponge powder. In participant evaluations, 93% agreed the product delivered results comparable to a professional in-office procedure. Despite the positive trial findings, Dermata shares dropped 22.86% to $0.6633.
Investors will monitor whether commercial sales of Tome Foundational Treatment gain traction through its online storefront and subscription options. Future updates on brand expansion and additional direct-to-consumer skincare product launches will serve as key benchmarks for company progress.
Key points
- Dermata Therapeutics reported positive topline results from an open-label cosmetic trial of 31 participants evaluating Tome Foundational Treatment.
- Over 71% of study participants showed overall skin improvement after just one application, with no treatment-related adverse events reported.
- In self-evaluations, 93% of participants considered the results comparable to a professional in-office procedure.
- Shares of Dermata Therapeutics fell 22.86% to $0.6633 following the release of the clinical findings.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What were the trial results for Dermata's Tome Foundational Treatment?
In a 31-participant study, over 71% of participants showed overall skin improvement after one treatment. After four weekly uses, subjects had visible gains in fine lines, dark spots, firmness, and radiance, with zero treatment-related adverse events.
How is Dermata selling Tome Foundational Treatment?
Dermata sells the once-weekly treatment directly to consumers online as a single four-treatment package or through a discounted subscription program.
How did Dermata Therapeutics stock react to the news?
Dermata Therapeutics (DRMA) stock dropped 22.86% to $0.6633 following the release of the topline cosmetic trial results.